Sign In
Buy VOR
$13.44
-0.220 (-1.61%)
At Close: Jun 03, 2026
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
05:00pm, Monday, 01'st Jun 2026
BOSTON, Mass., June 01, 2026 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that, on June 1, 2026,
Vor Bio to Participate in the 2026 Jefferies Global Healthcare Conference
08:30am, Thursday, 28'th May 2026
BOSTON, May 28, 2026 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that it will provide a corpora
Interim analysis demonstrated a 55.0% relative reduction in proteinuria versus placebo at 39 weeks with eGFR remaining stable through treatment Results further support the potential for telitacicept
Vor Bio Reports First Quarter 2026 Financial Results and Provides Corporate Update
08:30am, Wednesday, 13'th May 2026
Enrollment on track for Phase 3 UPSTREAM MG trial of telitacicept in generalized myasthenia gravis patients with topline results anticipated in 1H27 Enrollment ongoing for Phase 3 UPSTREAM SjD of teli
Wall Street Analysts Believe Vor Biopharma (VOR) Could Rally 124.59%: Here's is How to Trade
10:55am, Thursday, 07'th May 2026
The consensus price target hints at a 124.6% upside potential for Vor Biopharma (VOR). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings est
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
04:30pm, Monday, 04'th May 2026
BOSTON, May 04, 2026 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that, on May 1, 2026, the Comp
Does Vor Biopharma (VOR) Have the Potential to Rally 117% as Wall Street Analysts Expect?
10:56am, Monday, 20'th Apr 2026
The average of price targets set by Wall Street analysts indicates a potential upside of 117% in Vor Biopharma (VOR). While the effectiveness of this highly sought-after metric is questionable, the po
Vor Biopharma Inc. (NASDAQ:VOR) Short Interest Update
02:20am, Wednesday, 15'th Apr 2026
Vor Biopharma Inc. (NASDAQ: VOR - Get Free Report) was the target of a large growth in short interest in March. As of March 31st, there was short interest totaling 5,687,983 shares, a growth of 66.5%
Ra Capital Management, L.P. Sells 484,104 Shares of Vor Biopharma (NASDAQ:VOR) Stock
04:19am, Sunday, 12'th Apr 2026
Vor Biopharma Inc. (NASDAQ: VOR - Get Free Report) Director Ra Capital Management, L.P. sold 484,104 shares of Vor Biopharma stock in a transaction on Wednesday, April 8th. The shares were sold at an
Ra Capital Management, L.P. Sells 135,201 Shares of Vor Biopharma (NASDAQ:VOR) Stock
04:19am, Sunday, 12'th Apr 2026
Vor Biopharma Inc. (NASDAQ: VOR - Get Free Report) Director Ra Capital Management, L.P. sold 135,201 shares of the stock in a transaction on Thursday, April 9th. The shares were sold at an average pri
Vor Biopharma: It's A Game Of Wait And See
03:38pm, Wednesday, 08'th Apr 2026
Vor Biopharma Inc. has pivoted to immunology, raising over $500m in 2025 to advance telitacicept for U.S. approval. VOR holds $530m cash, extending its runway into 2029, but faces significant dilution
First Look: Pershing's UMG bid, Fed hawkish signals, GLP‑1 pill momentum
07:37am, Tuesday, 07'th Apr 2026
Stock News Markets edge higher before Iran deadline: Global equities were mixed and oil volatile ahead of President Trump's deadline on Iran's Hormuz reopening,
Vor Biopharma Inc. (NASDAQ:VOR) Given Consensus Recommendation of “Moderate Buy” by Analysts
02:58am, Monday, 06'th Apr 2026
Shares of Vor Biopharma Inc. (NASDAQ: VOR - Get Free Report) have earned a consensus rating of "Moderate Buy" from the thirteen ratings firms that are covering the stock, Marketbeat reports. One equit
Vor Biopharma (VOR) Upgraded to Buy: Here's Why
01:01pm, Thursday, 02'nd Apr 2026
Vor Biopharma (VOR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Wall Street Analysts Predict a 107.82% Upside in Vor Biopharma (VOR): Here's What You Should Know
10:56am, Thursday, 02'nd Apr 2026
The average of price targets set by Wall Street analysts indicates a potential upside of 107.8% in Vor Biopharma (VOR). While the effectiveness of this highly sought-after metric is questionable, the
